BIOFRONTERA INC (BFRI) Stock Price, Forecast & Analysis
USA - NASDAQ:BFRI - US09077D2099 - Common Stock
BFRI Key Statistics, Chart & Performance
The current stock price of BFRI is 0.8177 USD. In the past month the price decreased by -14.82%. In the past year, price increased by 11.4%.
BFRI Latest News, Press Relases and Analysis
BFRI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.55 | 3.94B |
Related stock screener links
About BFRI
Company Profile
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2021-10-14. The firm is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The firm's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and is used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
Company Info
BIOFRONTERA INC
120 Presidential Way,, Suite 330
Woburn MASSACHUSETTS US
CEO: Erica Monaco
Employees: 92
Phone: 17812451325
BIOFRONTERA INC / BFRI FAQ
What does BFRI do?
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2021-10-14. The firm is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The firm's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and is used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
What is the stock price of BIOFRONTERA INC today?
The current stock price of BFRI is 0.8177 USD. The price decreased by -8.13% in the last trading session.
Does BFRI stock pay dividends?
BFRI does not pay a dividend.
What is the ChartMill rating of BIOFRONTERA INC stock?
BFRI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does BIOFRONTERA INC belong to?
BIOFRONTERA INC (BFRI) operates in the Health Care sector and the Pharmaceuticals industry.
When does BIOFRONTERA INC (BFRI) report earnings?
BIOFRONTERA INC (BFRI) will report earnings on 2026-03-19, after the market close.
Can you provide the ownership details for BFRI stock?
You can find the ownership structure of BIOFRONTERA INC (BFRI) on the Ownership tab.
BFRI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BFRI. When comparing the yearly performance of all stocks, BFRI turns out to be only a medium performer in the overall market: it outperformed 40.64% of all stocks.
BFRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BFRI. Both the profitability and financial health of BFRI have multiple concerns.
BFRI Financial Highlights
Over the last trailing twelve months BFRI reported a non-GAAP Earnings per Share(EPS) of -2.27. The EPS increased by 75.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.38% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BFRI Forecast & Estimates
8 analysts have analysed BFRI and the average price target is 6.12 USD. This implies a price increase of 648.44% is expected in the next year compared to the current price of 0.8177.
For the next year, analysts expect an EPS growth of 63.71% and a revenue growth 2.11% for BFRI